Compare WTM & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTM | APGE |
|---|---|---|
| Founded | 1980 | 2022 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | WTM | APGE |
|---|---|---|
| Price | $2,267.00 | $85.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | 12.1K | ★ 607.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.04% | N/A |
| EPS Growth | ★ 379.05 | N/A |
| EPS | ★ 430.14 | N/A |
| Revenue | ★ $3,735,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | ★ 66.76 | N/A |
| 52 Week Low | $1,648.00 | $34.34 |
| 52 Week High | $2,333.00 | $95.32 |
| Indicator | WTM | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 53.33 |
| Support Level | $2,012.62 | $73.06 |
| Resistance Level | $2,329.39 | $95.32 |
| Average True Range (ATR) | 42.04 | 3.49 |
| MACD | -5.36 | -0.85 |
| Stochastic Oscillator | 19.16 | 23.97 |
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.